Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
Related Posts
Publicis Lifts Sales Outlook on Further Market Share Gains
Publicis now expects organic net revenue growth of 5%-6% for the year, after second quarter sales beat analysts’ expectations, fueled by gains in market share.
Volvo Trims Profit Outlook
Carmaker Volvo cut its earnings expectations for 2025, citing complex market conditions and uncertainty around worldwide trade wars.
Boeing Talks to Buy Back Spirit AeroSystems Have Last-Minute Twist
The jet manufacturer has proposed using mostly stock to reacquire the supplier.